Arca
Skip to content
Tools
Tools

Epithelial ovarian cancer

Drug research and approvals for epithelial ovarian cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 600 studies of epithelial ovarian cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 600
  • Trials authorized in Canada: 26
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 600 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,869 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 437 whose ending is known, 28% met their primary endpoint, 11% missed it and 61% stopped early.

  • Completed, result not reported63134%
  • Ongoing53529%
  • Status unknown26614%
  • Stopped: other or unclear1267%
  • Met its primary endpoint1237%
  • Stopped: enrollment or feasibility553%
  • Missed its primary endpoint473%
  • Stopped: sponsor or business decision412%
  • Stopped: lack of efficacy292%
  • Stopped: funding131%
  • Stopped: safety3<1%

Trials authorized in Canada

The 10 newest of 26; search them all in Canada trials
Sep 23, 2026A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab)Merck & Co. (MSD)Pending
Aug 20, 2026A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab)AstraZeneca PharmaceuticalsPending
Dec 23, 2025A phase 1b/2 open-label, multicenter study to evaluate the safety and efficacy of raludotatug deruxtecan with or without other anticancer investigational…MK-5909 (raludotatug deruxtecan (r-dxd)) / Keytruda / Bevacizumab / Paclitaxel…Merck & Co. (MSD)Ongoing
Oct 20, 2025A randomised, open-label, phase III study of AZD5335 versus mirvetuximab soravtansine in fr-high and AZD5335 versus investigator’s choice chemotherapy in…AZD5335AstraZeneca PharmaceuticalsOngoing
Mar 29, 2023A phase 2 open-label study evaluating the efficacy and safety of luveltamab tazevibulin (STRO-002) in women with relapsed platinum-resistant epithelial ovarian…Luveltamab tazevibulin (STRO-002)Sutro BiopharmaOngoing
Jan 18, 2023A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced, platinum-resistant high-grade epithelial…Relacorilant (CORT125134) / PaclitaxelCorcept TherapeuticsOngoing
Dec 30, 202268ga-fapi pet/ct in the staging of high grade epithelial ovarian cancers: a pilot study68GA-PNT6555 [manufacturer designation: [GA-6S[-PNT65S5 injection]Princess Margaret Cancer CentreOngoing
Dec 14, 2022Phase 1 first-in-human study to explore the safety, tolerability, and pharmacokinetics of amg 794 in subjects with claudin 6 positive advanced/metastatic non…Amg 794AmgenPending
Nov 9, 2022Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy…Mirvetuximab soravtansineAbbVieOngoing
Sep 29, 2022Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate…Mirvetuximab soravtansine (IMGN853)AbbVieOngoing

FDA orphan designations

Approved first, then open designations, newest first
Nov 25, 2003AbagovomabTreatment of epithelial ovarian cancerMenarini Ricerche S.p.A.Designated
Feb 11, 2002Recombinant immunotoxin combining the functional components…Treatment of epithelial ovarian cancerNational Institutes of HealthDesignated
Nov 25, 1996Monoclonal antibody-B43.13Treatment of epithelial ovarian cancer.CanariaBio Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.